These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17102656)

  • 1. Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma.
    Koestenberger M; Gallistl S; Bettina L; Cimenti C; Kutschera J; Cvirn G
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):677-80. PubMed ID: 17102656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).
    Cvirn G; Cimenti C; Kutschera J; Ferstl U; Wagner T; Muntean W; Jurgens G; Gallistl S; Koestenberger M
    Eur J Pediatr; 2007 May; 166(5):427-31. PubMed ID: 17047995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
    Carlsson SC; Schulman S
    Semin Vasc Med; 2005 Aug; 5(3):259-65. PubMed ID: 16123913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
    Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
    Koestenberger M; Cvirn G; Gallistl S; Kutschera J; Muntean W
    Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
    Dorani H; Schützer KM; Sarich TC; Wall U; Logren U; Ohlsson L; Eriksson UG
    Eur J Clin Pharmacol; 2007 Jun; 63(6):571-81. PubMed ID: 17387462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
    Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
    Novak M; Schlagenhauf A; Bernhard H; Schweintzger S; Leschnik B; Muntean W
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):588-92. PubMed ID: 21799400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
    Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
    Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
    Teng R; Sarich TC; Eriksson UG; Hamer JE; Gillette S; Schützer KM; Carlson GF; Kowey PR
    J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.